Q-omics provides the consensus-scored ZSCAN21 profile across patient tissues and cancer cell-line models. ZSCAN21 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ZSCAN21 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, ZSCAN21 RNA expression shows 21,304 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, THCA, and ACC as cancer lineages where ZSCAN21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZSCAN21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZSCAN21 survival associations across molecular data types. ZSCAN21 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZSCAN21 RNA expression–survival associations across cancer types. High ZSCAN21 expression shows unfavorable associations in ACC, KICH and COAD, but favorable associations in BRCA, KIRC and LAML. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for ZSCAN21 RNA expression.
This table summarizes ZSCAN21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZSCAN21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZSCAN21 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, CHOL, LUSC and COAD. The THCA box plot shows higher ZSCAN21 RNA expression in normal versus tumor tissue (log2 FC = −1.056, t-test p < 0.001).
This table shows molecular features associated with ZSCAN21 in patient tissues and cancer cell lines. In patient samples, ZSCAN21 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZSCAN21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
